New Jersey-based pharmaceutical giant, Merck & Company, Inc. (NYSE: MRK)—ranked 72nd on the Fortune 500 list—manufactures a broad range of over-the-counter medicines as well as prescription drugs and adult and childhood vaccines for diseases such as measles, mumps, pneumonia, and shingles. In addition, Merck Animal Health makes a wide variety of veterinary products—all sold worldwide. Its current revenues are $39.5 billion.
When the company, which currently has 30,000 Avaya users among its 68,000 employees, sought an unbiased resource to maintain its Avaya systems while it evaluated its future direction, it sought the counsel of other pharmaceutical companies. Eventually, a source at Bayer Corporation (Philadelphia, PA), a Continuant customer since 2007, recommended Continuant. The rest is history.
Today, Continuant maintains all of Merck’s Avaya systems, and has done so since 2016. Merck knows that working with Continuant also means that there will be “no pressure to upgrade” its Avaya systems but rather, that Continuant will offer the best solutions for Merck, based on the company’s needs.
In addition, Merck cites both the high level of service and the cost-saving benefits of working with Continuant. Merck has realized a 60 percent cost savings over the OEM by having Continuant maintain and support its Avaya systems.
Merck will be migrating to a Cisco Unified Communications solution over the next several years; Continuant is positioned to offer world-class Continuant Managed Services for Cisco UC.